Clinical Development of Angiogenesis Inhibitors to Vascular Endothelial Growth Factor and Its Receptors as Cancer Therapeutics

Author(s): Zhenping Zhu, Peter Bohlen, Larry Witte

Journal Name: Current Cancer Drug Targets

Volume 2 , Issue 2 , 2002

Become EABM
Become Reviewer


Angiogenesis, the formation of new blood vessels, is essential for both tumor growth and metastasis. Recent advances in our understanding of the molecular mechanisms underlying the angiogenesis process and its regulation have led to the discovery of a variety of pharmaceutical agents with anti-angiogenic activity. The potential application of these angiogenesis inhibitors is currently under intense clinical investigation. Compelling evidence suggests that vascular endothelial growth factor (VEGF) and its receptors play critical roles in tumor-associated angiogenesis, and that they represent potential targets for therapeutic intervention. This has been demonstrated in a variety of animal tumor models in which disabling the function of VEGF and its receptors was shown to inhibit both tumor growth and metastasis. A number of agents designed specifically for targeting VEGF and / or its receptors are being evaluated in various clinical trials in cancer patients. This review will discuss the biology of the VEGF and its receptors, the mechanisms of action as well as the current status in clinical development of antagonistic agents to VEGF and its receptors. Included in this review are antagonistic antibodies, ribozymes, immunotoxins, and synthetic small molecular inhibitors.

Keywords: angiogenesis inhibitor, vegf, anti-angiogenic, vegfr, plgf, anti-vegfr-1flt-1-antibody

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2002
Page: [135 - 156]
Pages: 22
DOI: 10.2174/1568009023333881
Price: $65

Article Metrics

PDF: 5